RT Journal Article
SR Electronic
T1 ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell Lines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.20.22276663
DO 10.1101/2022.06.20.22276663
A1 Lucas, L.M.
A1 Cullum, R.L.
A1 Woggerman, J.N.
A1 Dwivedi, V.
A1 Markham, J.A.
A1 Kelley, C.M.
A1 Knerr, E.L.
A1 Cook, L.J.
A1 Lucas, H.C.
A1 Waits, D.S.
A1 Ghosh, T.M.
A1 Halanych, K.M.
A1 Gupta, R.B.
A1 Riese, D.J.
YR 2023
UL http://medrxiv.org/content/early/2023/06/23/2022.06.20.22276663.abstract
AB Metastatic skin cutaneous melanomas remain a significant clinical problem. In particular, those melanomas that do not contain a gain-of-function BRAF allele remain challenging to treat because of the paucity of targets for effective therapeutic intervention. Thus, here we investigate the role of the ERBB4 receptor tyrosine kinase in skin cutaneous melanomas that contain wild-type BRAF alleles (“BRAF WT melanomas”). We have performed in silico analyses of a public repository (The Cancer Genome Atlas - TCGA) of skin cutaneous melanoma gene expression and mutation data (TCGA-SKCM data set). These analyses demonstrate that elevated ERBB4 transcription strongly correlates with RAS gene or NF1 mutations that stimulate RAS signaling. Thus, these results have led us to hypothesize that elevated ERBB4 signaling which cooperates with elevated RAS signaling to drive BRAF WT melanomas. We have tested this hypothesis using commercially available BRAF WT melanoma cell lines. Ectopic expression of wild-type ERBB4 stimulates clonogenic proliferation of the IPC-298, MEL-JUSO, MeWo, and SK-MEL-2 BRAF WT melanoma cell lines, whereas ectopic expression of a dominant-negative (K751M) ERBB4 mutant allele inhibits clonogenic proliferation of these same cell lines. Ectopic expression of a dominant-negative ERBB4 mutant allele inhibits anchorage-independent proliferation of MEL-JUSO cells and ectopic expression of a dominant-negative ERBB2 mutant alleles inhibits clonogenic proliferation of MEL-JUSO cells. These data suggest that elevated signaling by ERBB4-ERBB2 heterodimers cooperates with elevated RAS signaling to drive the proliferation of some BRAF WT tumors and that combination therapies that target these two signaling pathways may be effective against these BRAF WT tumors.Competing Interest StatementDavid J. Riese II has been a consultant for Eli Lilly & Co., ImClone Systems, and Bristol-Myers Squibb.Funding StatementThis research has been funded by an Auburn University Internal Grants Program award to DJR, an Auburn University Research Initiative in Cancer (AURIC) fellowship to RLC, the US Department of Education GAANN Graduate Fellowship Program in Biological & Pharmaceutical Engineering Award No. P200A120244 to Auburn University, an Auburn University Presidential Graduate Research Fellowship to LML, and other support from AURIC, the Department of Drug Discovery and Development, and the Harrison College of Pharmacy.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Cancer Genome Atlas (TCGA) Skin Cutaneous Melanoma (SKCM) dataset: https://portal.gdc.cancer.gov/projects/TCGA-SKCMI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://portal.gdc.cancer.gov/projects/TCGA-SKCM